{"schema_version":"secwatch.filing_event.v1","accession":"0001603756-24-000061","form_type":"8-K","ticker":null,"cik":"0001603756","company_name":"Axonics, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.178384+00:00","generated_at":"2026-06-03T04:27:33.818130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axonics Q1 revenue $91.4M, up 29% YoY; gross margin record 75.8%","bullets":["Net loss $19.1M vs $9.2M prior year, includes $3.8M acquisition costs for Boston Scientific merger.","Sacral neuromodulation revenue $71.7M (+30%), Bulkamid revenue $19.7M (+27%).","Adjusted EBITDA $3.0M vs $0.9M prior year; $6M cash compensation added back due to halted equity grants.","Cash and investments $349M as of March 31, 2024; no guidance issued.","Pending merger with Boston Scientific; equity grants stopped Jan 2024, shifting $6M to cash compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001603756-24-000061","json":"https://secwatch.observer/filing/0001603756-24-000061.json","markdown":"https://secwatch.observer/filing/0001603756-24-000061.md","text":"https://secwatch.observer/filing/0001603756-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/0001603756-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/axnx-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:27:33.818130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f63f5a4dceebdcc874acb217a78675aa8680830","claim":"Axonics, Inc. reported three months ended March 31, 2024 results: revenue $91.4 million, net income Net loss was $19.1 million.","evidence_excerpt":"of Boston Scientific as we endeavor to bring our life-changing incontinence therapies to more patients than ever before.” First Quarter 2024 Financial Results • Net revenue was $91.4 million, an increase of 29% compared to the prior year period. ◦ Sacral neuromodulation revenue was $71.7 million, an increase of 30% compared to the prior year period. ◦ Bulkamid","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/0001603756-24-000061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$91.4 million"},{"label":"Net income","value":"Net loss was $19.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}